Tuberc Respir Dis.  2006 Mar;60(3):314-320.

The Relationship between Heme Oxygenase-1 Expression and Response to Cisplatin Containing Chemotherapy in Advanced Non-Small Cell Lung Cancer

• Yang DK
• Roh MS
• Lee KE
• Kim KN
• Lee KN
• Choi PJ
• Bang JH
• Kim BK
• Seo HR
• Kim MJ
• Kim SK
• Lee SK
• Son CH

Abstract

BACKGROUND: The overall response (20-30%) to chemotherapy in non-small cell lung cancer (NSCLC) is quite poor. Heme oxygenase-1 (HO-1) is the rate-limiting enzyme in heme degradation. There is increasing evidence suggesting that the induction of HO-1 might have an important protective effect against oxidative stress including cisplatin containing chemotherapy. This study retrospectively investigated the relationship between HO-1 expression and the response to chemotherapy containing cisplatinin advanced NSCLC patients. MATERIAL AND METHODS: The medical records including the responses to chemotherapy of fifty nine cases were evaluated retrospectively, and the tissue samples of these patients were immunohistochemically stained for HO-1.
RESULTS
Forty three of the fifty nine patients(72.8%) showed positive staining for HO-1 in their cancer tissues. There was no significant difference according to the cell type, stage and tumor size. In addition, there was no correlation between HO-1 expression and the responses to chemotherapy.
CONCLUSION
HO-1 expression in tumor tissue dose not predict the response to cisplatin containing chemotherapy in advanced NSCLC. Further prospective studies with a larger number of patients will be needed to confirm these results.

Keyword

Heme oxygenase-1; Non-small cell lung cancer; Cisplatin containing chemotherapy

MeSH Terms

Carcinoma, Non-Small-Cell Lung*
Cisplatin*
Drug Therapy*
Heme Oxygenase-1*
Heme*
Humans
Medical Records
Oxidative Stress
Retrospective Studies
Cisplatin
Heme
Heme Oxygenase-1

Figure

• 

  Figure 1 Immunohistochemical staining for HO-1. (A) negative HO-1 expression (×200), (B) positive HO-1 expression in adenocarcinoma (×200), (C) positive HO-1 expression in squamous cell carcinoma (×200), (D) positive HO-1 expression in non-small cell lung cancer (×200).

Reference

1. Korea National Statistical Office. Deaths and death rate by cause. 2004.

2. Minna JD. Neoplasms of the lung. Harrison's principles of internal medicine. 2005. 16th ed. New York: McGraw-Hill;506–515.

3. Scientific Committee of Korean Academy of Tuberculosis and Respiratory Diseases. The national survey of lung cancer in Korea. Tuberc Respir Dis. 1999. 46:455–465.

4. Graziano SL. Non-small cell lung cancer: clinical value of new biological predictors. Lung cancer. 1997. 17:S37–S58.

5. Fang J, Akaike T, Maeda H. Antiapoptotic role of heme oxygenase(HO) and the potential of HO as a target in anticancer treatment. Apoptosis. 2004. 9:27–35.

6. Liu ZM, Chen GG, Ng EK, Leung WK, Sung JJ, Chung SS. Upregulation of heme oxygenase-1 and p21 confers resistance to apoptosis in human gastric cancer cells. Oncogene. 2004. 23:503–513.

7. Agarwal A, Balla J, Alam J, Croatt AJ, Nath KA. Induction of heme oxygenase in toxic renal injury: a protective role in cisplatin nephrotoxicity in the rat. Kidney Int. 1995. 48:1298–1307.

8. Fang J, Sawa T, Akaike T, Greish K, Maeda H. Enhancement of chemotherapeutic response of tumor cells by a heme oxygenase inhibitor, pegylated zinc protoporphyrin. Int J Cancer. 2004. 109:1–8.

9. Mountain CF. Revisions in the international system for staging lung cancer. Chest. 1997. 111:1710–1717.

10. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981. 47:207–214.

11. Tenhunen R, Marver HS, Schmid R. The enzymatic conversion of heme to bilirubin by microsomal heme oxygenase. Proc Natl Acad Sci U S A. 1968. 61:748–755.

12. Alam J. Heme oxygenase-1: past, present, and future. Antioxid Redox Signal. 2002. 4:559–562.

13. Stocker R, MacDonagh AF, Glazer AN, Ames BN. Antioxidant activities of bile pigments: biliverdin and bilirubin. Methods Enzymol. 1990. 186:301–309.

14. Verma A, Hirsch DJ, Glatt CE, Ronnett GV, Snyder SH. Carbon monoxide: a putative neural messenger. Science. 1993. 259:381–384.

15. Applegate LA, Luscher P, Tyrrell RM. Induction of heme oxygenase: a general response to oxidant stress in cultured mammalian cells. Cancer Res. 1991. 51:974–978.

16. Nath KA, Balla G, Vercellotii GM, Balla J, Jacob HS, Levitt MD, et al. Induction of heme oxygenase is a rapid, protective response in rhabdomyolysis in the rat. J Clin Invest. 1992. 90:267–270.

17. Tanaka S, Akaike T, Fang J, Beppu T, Ogawa M, Tamura F, et al. Antiapoptotic effect of haem oxygenase-1 induced by nitric oxide in experimental solid tumour. Br J Cancer. 2003. 88:902–909.

18. Doi K, Akaike T, Fujii S, Tanaka S, Ikebe N, Beppu T, et al. Induction of heam oxygenase-1 by nitric oxide and ischaemia in experimental solid tumors and implications for tumour growth. Br J Cancer. 1999. 80:1945–1954.

19. Agarwal A, Balla J, Alam J, Croatt AJ, Nath KA. Induction of heme oxygenase in toxic renal injury: a protective role in cisplatin nephrotoxicity in the rat. Kidney Int. 1995. 48:1298–1307.

20. Yokoyama S, Mita S, Okabe A, Abe M, Ogawa M. Prediction of radiosensitivity in human esophageal squamous cell carcinomas with heme oxygenase-1: a clinicopathologic and immunohistochemical study. Oncol Rep. 2001. 8:355–358.

21. Yanagawa T, Omura K, Harada H, Nakaso K, Iwasa S, Koyama Y, et al. Heme oxygenase-1 expression predicts cervical lymph node metastasis of tongue squamous cell carcinoma. Oral Oncol. 2004. 40:21–27.